Arteriosclerotic Retinopathy is a series of changes in the retina that are caused by arteriosclerosis. It is characterized by bleeding in the retina, thick fluid oozing from the retina, impaired oxygenation of the retina, an abrupt reduction of blood flow to the heart muscle that may cause dying off of tissue (myocardial infarction), and hardening of the walls of the little arteries (arterioles) in the eye. These degenerative changes can cause vision impairment. .
In Arteriosclerotic Retinopathy the opening (lumen) of the little arteries (arterioles) in the retina is irregular. The retina is the layer of the eyeball that contains the light sensitive nerve cells. This layer also contains a large number of little blood vessels. This disorder causes thickening of the arterial walls which in turn causes the arterioles to become contorted.
Flame shaped or pinpoint spots of bleeding may also occur, although they are apparent only during examination of the eye with an ophthalmoscope. The retina may show oozing of thick liquid, and dying tissue (necrosis) in certain spots. The place where the optic nerve enters the retina (optic disk or papilla) as seen by the ophthalmologist, may be blurred. The retina may become detached, and arterial spasm may occur. Eventually internal bleeding or clotting (thrombosis) of the central vein and withering away (atrophy) of the retina may result, which can cause progressive vision impairment.
Arteriosclerotic Retinopathy usually occurs as a result of progressive hardening of the blood vessels by calcification and loss of elastic tissue (arteriosclerosis). Arteriosclerosis is a general term which includes a number of blood vessel diseases such as fatty degeneration of the arteries (atherosclerosis), and may also include changes in the shape of the arteries. With age, the blood vessels often become more contorted and less elastic. Certain biochemical, physical and environmental factors, known as risk factors may predispose an individual to arteriosclerosis.
Arteriosclerotic Retinopathy affects persons with fatty degeneration (atherosclerosis), and hardening of the arteries (arteriosclerosis). This type of Retinopathy usually affects people over age 50 years
Hypertensive Retinopathy is a syndrome of changes in the retina caused by hypertension. It is characterized by progressive changes in the little arteries (arterioles) of the eye and swelling (edema), resulting in vision impairment. (For more information, choose "hypertensive retinopathy" as your search term in the Rare Disease Database.)
Papilledema (Choked Disk) is a swelling (edema) of the portion of the retina where the optic nerve enters the eyeball. The swelling is due to increased pressure inside the skull that may be caused by a variety of conditions.
Therapy for Arteriosclerotic Retinopathy consists of treating the underlying arteriosclerosis. An excess of lipids in the blood (hyperlipidemia) can be prevented by changes in dietary habits. Fat intake should be reduced, and saturated fats should be replaced with polyunsaturated fats. The intake of cholesterol, saturated and short-chain fatty acids (such as those in meats or dairy products), should be reduced. Weight reduction to normal, or even slightly under current statistical norms, is recommended. Drugs may be required in certain patients to reduce blood cholesterol and lipids.
Prevention of arteriosclerosis is possible by good control of diabetes when present, and by weight loss if obesity is a factor. Cigarette smoking may also aggravate arteriosclerosis and should be limited or stopped. Regular exercise may be a helpful therapeutic measure. Hypertension should be identified and treated early.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Beers MH, Berkow R., eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:729.
REVIEW ARTICLE Bhagat N, et al., Central retinal vein occlusion: review of management. Eur J Ophthalmol. 1999;9:165-80.
JOURNAL ARTICLES Schimkat M, et al., [Mitral valve prolapse. A possible cause of retinal vascular occlusion in young patients]. Ophthalmologe. 1993;90:476-78. German.
Tomikawa S, et al., [Lipoprotein (a) and sclerotic changes in retinal arterioles]. Nippon Ganka Gakkai Zasshi. 1993;97:967-74. Japanese.
Rabb MF, et al., Retinal arterial macroaneurysms. Surv Ophthalmol. 1988;33:73-96.
Trushko IA., [Possibilities of the color stress test in the early diagnosis and evaluation of the effectiveness of treatment of arteriosclerotic retinal dystrophies]. Oftalmol Zh. 1986;4:229-231.
National Association for Visually Handicapped 22 West 21st Street New York, NY 10010 USA Tel: (212)889-3141 Fax: (212)727-2931 Email: staff@navh.org Internet: http://www.navh.org
Schepens Eye Research Institute 20 Staniford Street Boston, MA 02114-2500 Tel: (617)912-0100 Fax: (617)912-0101 Email: geninfo@vision.eri.harvard.edu Internet: http://www.theschepens.org/
American Council of the Blind, Inc. 1155 15th Street Suite 1004 Washington, DC 20005 Tel: (202)467-5081 Fax: (202)467-5085 Tel: (800)424-8666 Internet: http://www.acb.org
American Foundation for the Blind 11 Penn Plaza Suite 300 New York, NY 10001 Tel: (212)502-7600 Fax: (212)502-7777 Tel: (800)232-5463 TDD: (212)502-7662 Email: afbinfo@afb.org Internet: http://www.afb.org
Council of Families with Visual Impairment 1155 15th St. NW Suite 1004 Washington, DC 20005 Tel: (202)465-5081 Fax: (202)465-5085 Email: info@acb.org Internet: http://www.acb.org/
American Heart Association National Center 7272 Greenville Avenue Dallas, TX 75231-4596 Tel: (214)373-6300 Fax: (214)373-0268 Tel: (800)242-8721 Email: inquire@heart.org Internet: http://www.americanheart.org
National Eye Research Foundation 910 Skokie Boulevard Suite 207A Northbrook, IL 60062 Tel: (847)564-4652 Fax: (847)564-0807 Tel: (800)621-2258 Email: nerf1955@aol.com Internet: http://www.nerf.org
NIH/National Eye Institute Building 31 Rm 6A32 31 Center Dr MSC 2510 Bethesda, MD 20892-2510 United States Tel: (301)496-5248 Fax: (301)402-1065 Email: 2020@nei.nih.gov Internet: http://www.nei.nih.gov/
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). CIGNA members can access the complete report by logging into myCIGNA.com. For non-CIGNA members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email orphan@rarediseases.org
Last Updated: 4/14/2008 Copyright 1987, 1989, 2000 National Organization for Rare Disorders, Inc.
This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.